Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Peri- and Postoperative Treatment With Histamine Dihydrochloride and Low-dose Interleukin-2 in Patients With Primary Resectable Pancreatic Cancer

NCT05810792 is registered in ClinicalTrials.gov with Sahlgrenska University Hospital as lead sponsor.

NCT NCT05810792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05810792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Peri- and Postoperative Treatment With Histamine Dihydrochloride and Low-dose Interleukin-2 in Patients With Primary Resectable Pancreatic Cancer
Lead sponsor
Sahlgrenska University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2024
Completion date
April 1, 2028
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immunosuppression, metastasis, pancreatic cancer, surgery